BRAK LABS Peptide research, plainly written

safety record

GHK-Cu: what has been measured about safety

The safety record for GHK-Cu, read as a record: what the two human trials do and do not report, what FDA said about the injected form and why that sentence gets misread in both directions, and the copper question nobody has measured.

Last Reviewed Editorial policy Methodology

GHK-Cu has more completed human testing behind it than most compounds in this catalog, and almost none of it answers a safety question. Two randomized trials ran to completion, in 1992 and 2006, at 86 evaluable and 13 completed patients [1] [2]. Neither abstract reports a safety or tolerability endpoint, and neither paper is open access, so what either study recorded on that question cannot be read.

That is a gap in what is readable rather than a finding in either direction, and the two are not the same thing. An abstract that omits safety is not a study that reported none.

What can be reported is more specific: one agency statement about the injected form that is routinely misread in both directions, a toxicology record that consists of remarks made inside efficacy experiments, and a copper exposure question that nobody has measured in a person on any route.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Every sentence below reports what a named source measured or stated, in what system, and what it found. Where the answer is that nobody has looked, the page says which study would have looked and names the document recording that it was not done.

This page publishes no dose, no schedule, no route instruction and no list of people who should avoid anything. A list of who should not use a compound is a directions-for-use document, and it only makes sense if the reader is going to use the thing. What replaces it is a description of the compound and its record, written about the molecule rather than about the reader.

One distinction runs through everything here and is worth fixing before the first section. Topically the compound is copper tripeptide-1, a listed cosmetic ingredient. In a vial for injection it is an unapproved drug, and FDA's only harm-adjacent statement is about that form and nothing else. A sentence about one route is not a sentence about the other.

What has been measured

What the two human trials report

Both randomized trials were conducted in patients and both completed. The 1992 trial ran to 86 evaluable patients with venous stasis ulcers; the 2006 trial ran to 13 completed patients after CO2 laser resurfacing [1] [2].

Neither abstract reports a safety or tolerability endpoint, and neither publisher serves the full paper to an unauthenticated request. PubMed Central, Europe PMC, OpenAlex, Semantic Scholar and both publishers' own sites were checked at the registered DOI on 8 August 2026, and neither trial is open access anywhere. So this page cannot say what either study recorded about adverse events, and does not guess.

One thing those two trials do establish, and it belongs here rather than in the benefits section: roughly a hundred people have received a copper-peptide preparation under a written protocol, in two studies, on the skin. That is the whole documented human exposure, and it is topical. [Human RCT] [1] [2]

What FDA has said about the injected form

The one agency statement that addresses harm rather than paperwork is FDA's rationale for placing the injectable form in category 2, bulk drug substances that may present significant safety risks. In the agency's own words: compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and there are limited data in humans to inform safety-related considerations [25].

Two things about that sentence get lost in roughly equal numbers, in opposite directions. The first is its scope: it addresses injectable routes, and a cosmetic cream is outside it entirely. The second is its strength: the agency wrote may pose, which records a possibility it has not excluded rather than an outcome it has observed.

The word aggregation carries the whole of that concern, so it is worth translating. Peptides can stick to one another and form larger particles, and a larger particle is likelier to draw an immune response than a single small molecule is. Whether this compound does that has not been tested, which is why the agency's sentence names the possibility instead of a result.

What the toxicology record contains

There is no formal toxicology package for this compound in any species. What the record holds instead is a pair of remarks made inside efficacy studies. The 2024 silicosis paper's abstract carries the phrase without significant systemic toxicity, describing its mice [12], and it names no toxicological endpoint, no exposure and no measurement behind that phrase. The rat knee study's abstract records no adverse finding in either direction, in an experiment built to measure ligament healing rather than harm [11].

Neither remark is a toxicology result, and neither paper claims otherwise. A toxicology study is designed the other way round: it sets out to find harm, it looks for it at several exposures, and it reports what it found at each one. Both of these experiments were built to measure whether something healed, and a sentence about adverse findings inside such a study is an aside rather than a result.

No acute toxicity study, no repeat-dose study, no genotoxicity study, no developmental and reproductive study and no carcinogenicity study of GHK-Cu was located in any species. [Animal] [11] [12]

The copper question, which is specific to this molecule

The metal is why this compound's exposure question is not the ordinary peptide one. Copper is required in small amounts and harmful in large ones, so the answer turns on quantity and frequency rather than on presence, which means it cannot be answered without a number.

That number does not exist. Two ex vivo studies measured how much copper crosses removed human skin and returned answers far apart from each other [3] [5], which leaves even the amount arriving unsettled. Downstream of it, no published work reports a copper level in the blood or the tissue of anybody using a GHK-Cu product, by either route.

None of that says harm has been observed. It says the measurement that would settle the question has never been taken, which is why the organ sections below read the way they do. [In-vitro] [3] [5]

Liver, kidney and the organs copper actually reaches

Searches about this compound cluster on the liver and the kidneys, and the reason is the copper rather than the peptide. Copper is handled by the body through specific organs, so a question about copper exposure is a question about those organs. What follows is what the published record on this compound holds about each, which in both cases is less than the question deserves.

Liver

No study of GHK-Cu in any species reports a liver endpoint. No serum alanine aminotransferase, no bilirubin, no liver weight, no histology. The study type that collects all four as a matter of routine is the repeat-dose toxicity study, and none exists for this compound.

The two human trials cannot fill that gap either. Neither abstract reports a safety endpoint of any kind, and neither paper can be read [1] [2], so there is no liver observation in the human record to report in either direction.

The honest version of why people ask is worth writing down rather than dodging. Copper that reaches the bloodstream is handled largely by the liver, which is the organ a copper-loading question is really about. That is general biochemistry rather than a finding about this compound, and the specific measurement that would connect it to GHK-Cu, serum or tissue copper in a person using a GHK-Cu product, has never been made [3] [5]. So the chain of reasoning that would take someone from a copper peptide to a liver effect is missing its only measured link, in both directions.

Kidney

The same answer, from the same absence. No published study of GHK-Cu in any species reports serum creatinine, urea, urinalysis or renal histology, because no study was designed to collect them.

Nothing in the human record reaches the question either. The 1992 trial measured ulcer size and the 2006 trial measured erythema, wrinkles and skin quality [1] [2]; neither measured renal function, and neither abstract reports whether anything renal was watched.

So there is no renal finding for GHK-Cu, positive or negative, and there is no study that could have produced one.

Skin, which is where the documented exposure actually is

Almost all documented human exposure to this compound is topical, so the skin is the one surface where a question about it can be answered with human data at all. Roughly a hundred people received a copper-peptide preparation on the skin across the two randomized trials [1] [2].

What those trials measured was whether it worked, not whether it was tolerated: ulcer closure in 1992, and resolution of redness, wrinkles and skin quality after laser resurfacing in 2006. Neither separated from its control on a measure an assessor or an instrument made, which is a result about effect rather than about tolerability. Neither abstract reports a dermatological adverse event rate, so the topical tolerability question has the same answer as every other question on this page: the study exists, and the number is not readable. [Human RCT] [1] [2]

What has not been characterised

Set out plainly, so the shape of the gap is visible rather than implied. There is no pharmacokinetic study of administered GHK-Cu in a person on any route, so nothing is published on how much reaches the blood, how long it stays, or what the body does with it. No serum or tissue copper measurement exists for anyone using a GHK-Cu product.

Identity sits underneath all of it. The public chemistry databases hold several records for this complex at different charges and stoichiometries, so there is no one agreed description of what the molecule is. Impurities are described against a composition, and a composition described several ways cannot anchor that description, which is the gap behind FDA's mention of aggregation and peptide-related impurities [25]. Nothing published measures how the material holds up over time either: no stability or shelf-life study was located in any presentation, and no degradation product has a characterisation.

No species has been followed long enough to describe what repeated exposure does. The published animal studies ran days to weeks, and the longest human assessment on record is twelve weeks.

Our takeThe two sentences most often quoted about this compound's safety are FDA's category 2 rationale and the absence of reported harm, and both get read as more than they say. The agency's sentence is about injection, it names a risk it has not ruled out rather than one it has measured, and it says in the same breath that human data are limited. The absence of reported harm is an absence of reporting: the topical form is a cosmetic ingredient nobody files adverse events against, and the injected form moves through a channel that does not report to FDA either.

Talk to a licensed clinician about anything concerning your health.

Frequently asked questions

Does GHK-Cu affect the liver?

Nothing published measures it. No study of GHK-Cu in any species reports liver enzymes, bilirubin, liver weight or histology, and the repeat-dose toxicity study that would collect all four does not exist for this compound. Neither of the two randomized human trials reports a safety endpoint of any kind, and neither paper is readable [1] [2]. The copper in the molecule is the reason the question gets asked, and the measurement that would connect the two, serum or tissue copper in a person using a GHK-Cu product, has never been made [3] [5].

Does GHK-Cu affect the kidneys?

No published study of GHK-Cu in any species reports serum creatinine, urea, urinalysis or renal histology. The two human trials measured ulcer closure and skin appearance and reported no renal endpoint [1] [2]. So there is no renal finding for this compound in either direction, and no study that could have produced one.

Can too much copper build up from using GHK-Cu?

Nobody has measured it, and the question cannot be answered from the published record. Copper is an essential trace element at low intake and toxic at high intake, so the answer depends on how much arrives and how often. Two ex vivo studies measured copper crossing removed human skin and disagreed with each other by a wide margin [3] [5], which leaves the input side unsettled, and no published study has measured serum or tissue copper in anyone using a topical or injected GHK-Cu product.

Is injected GHK-Cu treated differently from the cream?

Yes, and by the agency rather than by this site. FDA placed the injectable form in category 2, bulk drug substances that may present significant safety risks, and its stated rationale is that compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities, with limited data in humans to inform safety-related considerations [25]. That statement is about injectable routes and nothing else. Topically the compound is copper tripeptide-1, a listed cosmetic ingredient.

Can GHK-Cu and KPV be used together?

No study has ever given the two together to anything, in any species, so there is no published record of the combination to report. Each record is thin in a different way, and each is set out where its sources are: GHK-Cu has two completed randomized human trials whose abstracts report no safety endpoint [1] [2], and what the KPV record holds is set out, with its sources, on the KPV safety record, linked under Safety records this page refers to at the foot of this page. Neither of those pages says anything about what the two do in combination, and a combination is a third thing rather than the sum of two.

Have any side effects of GHK-Cu been reported?

Not in a form this page can report. The two randomized trials do not publish a tolerability endpoint in their abstracts and their full texts are not readable [1] [2], the animal work consists of efficacy experiments that mention adverse findings only in passing [11] [12], and there is no formal toxicology package in any species. The absence of reported harm here is an absence of reporting rather than a measured result.

What would change what this page says?

Access to either trial's full text would, immediately, because both studies may well have recorded tolerability data that is simply not in the abstract. So would a formal toxicology study in any species, which would be the first. And so would any measurement of serum or tissue copper in a person using a GHK-Cu product, which is the single missing link in the question readers are actually asking.

References

  1. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PMID 1495150 DOI 10.1067/mva.1992.37086
  2. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171 DOI 10.1001/archfaci.8.4.252
  3. Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010. PMID 20703511 DOI 10.1007/s00011-010-0214-4
  4. Mazurowska L, Mojski M. Biological activities of selected peptides: skin penetration ability of copper complexes with peptides. J Cosmet Sci. 2008. PMID 18350235
  5. Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015. PMID 25690343 DOI 10.1007/s11095-015-1652-z
  6. Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 2025. PMID 39795193 DOI 10.3390/molecules30010136
  7. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992. PMID 1522753 DOI 10.1016/0024-3205(92)90504-i
  8. Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2012. PMID 23285694
  9. Gruchlik A, Chodurek E, Dzierzewicz Z. Effect of GLY-HIS-LYS and its copper complex on TGF-β secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2014. PMID 25745767
  10. Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012. PMID 23019153 DOI 10.1002/psc.2455
  11. Fu SC, Cheuk YC, Chiu WY, Yung SH, Rolf CG, Chan KM. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015. PMID 25731775 DOI 10.1002/jor.22831
  12. Bian Y, Deng M, Liu J, Li J, Zhang Q, Wang Z, Liao L, Miao J, Li R, Zhou X, Hou G. The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol. 2024. PMID 38879894 DOI 10.1016/j.redox.2024.103237
  13. Ma WH, Li M, Ma HF, Li W, Liu L, Yin Y, Zhou XM, Hou G. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2020. PMID 31809714 DOI 10.1016/j.lfs.2019.117139
  14. Deng M, Zhang Q, Yan L, Bian Y, Li R, Gao J, Wang Y, Miao J, Li J, Zhou X, Hou G. Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. J Cachexia Sarcopenia Muscle. 2023. PMID 36905132 DOI 10.1002/jcsm.13213
  15. Zhang Q, Liu J, Deng MM, Tong R, Hou G. Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells. Biomed Pharmacother. 2023. PMID 37257226 DOI 10.1016/j.biopha.2023.114936
  16. Wen H, Zhao K, Luo X, Pu J, Li Y, Dou Y, He J, Nie X, Ke Y, Zhou W. The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways. Biogerontology. 2026. PMID 42084774 DOI 10.1007/s10522-026-10444-x
  17. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014. PMID 25302294 DOI 10.1155/2014/151479
  18. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. PMID 26236730 DOI 10.1155/2015/648108
  19. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012. PMID 22666519 DOI 10.1155/2012/324832
  20. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID 18644225 DOI 10.1163/156856208784909435
  21. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim do W, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016. PMID 27489425 DOI 10.5021/ad.2016.28.4.438
  22. Hudson Biotech. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults. Registry record read in full through the ClinicalTrials.gov API v2 on 8 August 2026 and re-read on 30 August 2026: registered as recruiting, actual start 2 February 2026, estimated primary completion 14 February 2027, no results posted, no update since it was first posted on 27 February 2026. The record carries no disclaimer of its own; read it with the sponsor account in reference 30. ClinicalTrials.gov, NCT07437586. 2026. Source document
  23. Austin Institute for Clinical Research. A Phase IV Open-label Trial Assessing the Impact on Skin Quality, Hydration, and Barrier of Three (3) Hydrafacial Treatments in Adults of Fitzpatrick Skin Types I-VI. Registry record read in full through the ClinicalTrials.gov API v2 on 8 August 2026: completed 9 October 2024, 27 participants, no results posted. Three interventions, of which one is a drug: a booster serum whose registered description lists the compound among its ingredients, applied to every participant. ClinicalTrials.gov, NCT05932732. 2024. Source document
  24. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Document updated 14 May 2026, carrying the category 1 list and the GHK-Cu withdrawal and clarification history. FDA human drug compounding. 2026. Source document
  25. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Category 2 of the bulk substances nominated under sections 503A or 503B, with the table of substances previously in category 2 whose nominations were withdrawn. Page content current 22 April 2026. FDA human drug compounding. 2026. Source document
  26. US Food and Drug Administration. Questions for PCAC regarding whether FDA should include certain bulk drug substances on the 503A Bulks List, Pharmacy Compounding Advisory Committee, 23 and 24 July 2026. Seven substances are put to a vote across four sessions, two questions each: BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and semax. Read in full on 8 August 2026; a case-insensitive search for GHK returns nothing. FDA advisory committee materials. 2026. Source document
  27. US Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated. Page content current 18 November 2025. FDA cosmetics laws and regulations. 2025. Source document
  28. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973. PMID 4349963
  29. LifeWave, Inc. A Two-part Study Investigating the Effect of the X39 Patch on Circulating Blood Levels of GHK and GHK-Cu in a Healthy Adult Population. Registry record read in full through the ClinicalTrials.gov API v2 on 8 August 2026: not yet recruiting, estimated start January 2027, 100 participants estimated. Its four primary outcomes are changes in circulating GHK and GHK-Cu levels from baseline to day 8, so the compound is the quantity measured rather than the intervention. ClinicalTrials.gov, NCT07706361. 2026. Source document
  30. US National Library of Medicine. ClinicalTrials.gov registry, API v2, sponsor search read in full on 30 August 2026. A search for the sponsor of NCT07437586 returns eight records: NCT07437547, NCT07437560, NCT07437586, NCT07467447, NCT07481734, NCT07481747, NCT07487363 and NCT07505745. Three describe themselves in their own registered text as an example record, a mock study or a fictional study. Two carry Eli Lilly protocol identifiers for Lilly molecules. All eight are recruiting, single-site at Peking University Shenzhen Hospital, first posted between 27 February and 1 April 2026, never amended since, and list the same central contact at an email domain that does not match the sponsor name. ClinicalTrials.gov. 2026. Sponsor search